Hatch-Waxman Patent Litigation
Patent Strategy & Management
Bruce Wexler is the Global Co-Chair of the Intellectual Property practice at Paul Hastings, overseeing the firm's 100-plus lawyer IP practice. He is a trial lawyer with extensive experience litigating high-stakes patent cases in a range of technologies. He has represented clients as lead counsel in patent cases involving multi-million and multi-billion dollar drug products.
Mr. Wexler is recognized as a top patent trial lawyer in the nation. He is lauded by Chambers and Partners as "incredibly innovative and smart" for his work in the life sciences sector, including in Hatch Waxman and BPCIA cases, with Chambers noting that he is "very good at thinking ahead and formulating a strategy." Mr. Wexler is recognized as a "consummate first chair trial attorney" and "a superb writer" who "really has the complete arsenal of skills" by Legal 500 for his litigation and life sciences patent expertise, with clients noting his ability to strategize and synthesize complex ideas in a clear manner. He has been recognized by Intellectual Asset Management's IAM Patent 1000, Managing Intellectual Property IP Stars, Benchmark Litigation, and has been named LMG Life Sciences' General Patent Litigator of the Year – New York. In addition to being repeatedly named a Life Sciences Star, Mr. Wexler was also recognized as The American Lawyer's 2015 Transatlantic Lawyer of the Year – IP. Mr. Wexler has been named a 2019 New York Trailblazer by New York Law Journal and was recognized as a 2020 IP Leader by IAM Global Leaders. He has also led his practice to win the LMG Life Sciences' Hatch Waxman Litigation Firm of the Year award both in 2018 and 2020.
He forms close partnerships with his clients to achieve successful outcomes, including in bet-the-company cases. He has litigated against virtually every generic drug company, and has helped his clients with important drug products such as Aricept®, Pradaxa®, Mirapex®, Cyltezo®, Basaglar®, Entereg®, Emend® oral and Emend® for Injection, Aciphex®, Banzel®, Gocovri®, and Opsumit®. He also regularly provides clients with personalized in-house CLE presentations on a variety of topics of interest.
Mr. Wexler is a former law clerk to the Chief Judge of the Court of Appeals for the Federal Circuit. He advised Congress and key stakeholders in the enactment of certain aspects of the AIA. In the Spring, he co-teaches an advanced patent law class ("Life Sciences and the Patent Law") as an Adjunct Professor at New York University School of Law.
Mr. Wexler received a B.S., summa cum laude, from Rensselaer Polytechnic Institute and a J.D., magna cum laude, from New York University School of Law.